


Fewer major bleeds with once- versus twice-daily enoxaparin

February 6 2017



(HealthDay)—Once-daily enoxaparin is associated with fewer major

bleeds than enoxaparin twice daily in patients with acute venous thromboembolism (VTE), according to a study published online Jan. 25 in the *Journal of Thrombosis and Haemostasis*.

Javier Trujillo-Santos, M.D., Ph.D., from the Hospital General Universitario Santa Lucía in Murcia, Spain, and colleagues assessed data from the RIETE registry for 4,730 patients receiving enoxaparin: 3,786 and 944 received enoxaparin twice and once daily, respectively.

The researchers found that, compared with those receiving enoxaparin twice daily, once-daily enoxaparin correlated with a trend toward more VTE recurrences (odds ratio [OR], 1.79; 95 percent confidence interval [CI], 0.55 to 5.88), fewer major bleeds (OR, 0.42; 95 percent CI, 0.17 to 1.08), and fewer deaths (OR, 0.32; 95 percent CI, 0.13 to 0.78) during the first 15 days. Patients on enoxaparin once daily had more VTE recurrences (OR, 2.5; 95 percent CI, 1.03 to 5.88), fewer major bleeds (OR, 0.40; 95 percent CI, 0.17 to 0.94), and fewer deaths (OR, 0.58; 95 percent CI, 0.33 to 1.00) at day 30. On propensity analysis, [patients](#) on enoxaparin once daily had fewer bleeds at 15 and 30 days (hazard ratios, 0.30 [95 percent CI, 0.10 to 0.88] and 0.16 [95 percent CI, 0.04 to 0.68]) and fewer deaths at 15 and 30 days (hazard ratios, 0.37 [95 percent CI, 0.14 to 0.99] and 0.19 [95 percent CI, 0.07 to 0.54]).

"Enoxaparin prescribed once daily results in fewer major bleeds than [enoxaparin](#) twice daily," the authors write.

The RIETE registry was supported by Sanofi Spain and Bayer Pharma AG.

More information: [Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Fewer major bleeds with once- versus twice-daily enoxaparin (2017, February 6)
retrieved 8 May 2024 from

<https://medicalxpress.com/news/2017-02-major-once-twice-daily-enoxaparin.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.